中文

MicroPort® Receives CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System

2019-04-15
Arnhem, the Netherlands – Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") is pleased to announce that its new generation Rapamycin Target Eluting Coronary Stent System Firehawk Liberty™ has received CE Mark on March 22, 2019.
 
The revolutionary third-generation drug eluting stent Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") is a result of eight-year R&D of MicroPort®, and it is a drug-eluting stent featuring strut in-groove coating and precision target drug-releasing patent technology. Firehawk® adopts unique abluminal laser-cut groove coating design and target-eluting technology, and combines the merits of bare metal stent and drug eluting stent, which allows Firehawk® to achieve the same clinical efficacy with significantly lower drug loading. In September 2018, the results of the Firehawk® TARGET AC European trial were published on the website of the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication nearly 200 years ago.
 
The new generation Rapamycin Target Eluting Coronary Stent System Firehawk Liberty™ introduces an improvement for its delivery system. It continues to feature the target drug eluting and adopts an innovative balloon technique to improve its dilation performance, which can further elevate the crossability, trackability and pushability of the product to make the stent more crossable with better vessel wall apposition after deployment.
 
Prior to Firehawk Liberty™, Firehawk® was granted the CE Mark in 2015. The approval for Firehawk Liberty™ in the European Union is set to help MicroPort® provide the physicians with more options in the field of PCI treatment. MicroPort® will continue to be committed to introducing more high-quality, innovative and high-end medical device products to the overseas markets, so as to provide patients with more comprehensive therapeutic solutions.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Copyright © 1998-2018 MicroPort Scientific Corporation. All rights reserved.

CONTACT:

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com

[Prev]:MicroPort® EP's PathBuilder™ Steerable Introducer Wins Approval from National Medical Products Administration of China (NMPA)

[Next]:The First Edition of MicroPort® Master Course Complex PCI Cross-Regional Program Ends Successfully